FASL anticorps
Aperçu rapide pour FASL anticorps (ABIN187307)
Antigène
Voir toutes FASL AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Clone
-
-
Specificité
- This antibody is specific for the extracellular domain of human Fas Ligand. Species Reactivity: Human. Others not tested.
-
Immunogène
- Recombinant human FasL (extracellular domain)
-
Isotype
- IgG1
-
-
-
-
Indications d'application
- Functional Activity: Inhibits apoptosis in anti-CD3 stimulated Jurkat T-cells ( 0.5 ~ 5 µg/mL) suitable. Excellent for neutralization. Flow cytometry: 1 x 106 H9 T-cells stained with 1 µg/mL antibody, followed by biotinylated goat anti-mouse IgG and streptavidin-PE. Immunocytochemistry Suggested starting dilution is >1:100 The optimal dilution for a specific application should be determined by the researcher.
-
Restrictions
- For Research Use only
-
-
-
Buffer
- 100 µg of 1 mg/mL affinity-purified monoclonal antibody. Prepared in 0.15M PBS, pH 7.2 with protein stabilizer. Purity 95% by SDS-PAGE.
-
Stock
- 4 °C
-
-
- FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))
-
Autre désignation
- CD178 / Fas Ligand
-
Sujet
- Fas (CD95/APO-1) Ligand (FasL) is a 43 kDa type II membrane protein and member of the tumor necrosis factor family. Human FasL can be released from cells as a 26 kDa soluble protein upon cleavage by metalloproteinases. FasL is expressed on various cells including T cells, NK cells, Monocytes, Sertoli cells and tumor cells. Interaction of FasL with its receptor triggers rapid apoptosis. FasL-induced apoptosis is involved in T cell receptor/anti-CD3 induced cell death, cytotoxic T cell activity, maintainence of immune privilege, immune escape of tumor cells and viral hepatitis. Malfunction of the Fas system causes hyperplasia.
-
Pathways
- Apoptose, EGFR Signaling Pathway, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity
Antigène
-